MoonLake Immunotherapeutics (MLTX) has provided an announcement.
MoonLake Immunotherapeutics has announced a breakthrough in its Phase 2 trials, as U.S. FDA and E.U. European Medicines Agency have backed its plan to move into Phase 3 with its pioneering Nanobody® sonelokimab for treating hidradenitis suppurativa. This unanimous support marks a significant step forward in the development of new treatments for this chronic skin condition, signaling potential growth and advancements for the company in the biopharmaceutical sector.
For detailed information about MLTX stock, go to TipRanks’ Stock Analysis page.